開示日時：2022/04/04 15:00:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.03 | 46,683,800 | 8,817,300 | 8,817,300 | 134.53 |
| 2019.03 | 45,926,700 | 5,788,400 | 5,788,400 | 122.39 |
| 2020.03 | 48,273,200 | 8,323,900 | 8,323,900 | 102.58 |
| 2021.03 | 51,595,200 | 7,122,400 | 7,122,400 | 141.5 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 1,407.0 | 1,409.62 | 1,874.71 | 9.83 | 11.12 |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.03 | 8,106,600 | 9,342,000 |
| 2019.03 | 3,579,700 | 4,871,100 |
| 2020.03 | 3,277,700 | 4,612,800 |
| 2021.03 | 12,479,500 | 13,560,100 |
※金額の単位は［万円］
▼テキスト箇所の抽出
April 4, 2022 Sumitomo Pharma Co., Ltd. Notification of Valuation Loss on Investment Securities Recorded in Company’s Non-consolidated Financial Statements (Japanese GAAP) Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that the Company will record a valuation loss on investment securities in its non-consolidated financial statements (Japanese GAAP) for the fiscal year ended March 31, 2022 as described below, treating it as an impairment loss. In addition, there will be no impact on consolidated profit or loss. 1. Details of Valuation Loss on Investment Securities In the non-consolidated financial statements (Japanese GAAP) for the fiscal year ended March 31, 2022, the Company will record an extraordinary loss of 65,920 million yen on stock holdings whose market value has significantly decreased within the Company’s investment securities, treating it as an impairment loss. 2. Impact on the Company’s Consolidated Profit or Loss As the Company prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS), there will be no impact on consolidated profit or loss. Contact: Corporate Communications Sumitomo Pharma Co., Ltd. TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)
